Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daridorexant adjunctive therapy with buprenorphine maintenance for opioid use disorder
2024-517482-16-00Phase 2Authorised
- Sponsor
- Linköping University
- Start
- Apr 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of daridorexant and buprenorphine in opioid use disorder (OUD) (2 arms), sponsored by Linköping University. Primary endpoint: Frequency of negative urine samples. Planned start Apr 2025; status: authorised.
02
Drugs
daridorexantbuprenorphine
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on 2024-517482-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517482-16-00.